Sudan

Population 2018: 42 million

### Tuberculosis profile

#### Estimates of TB burden, 2018

<table>
<thead>
<tr>
<th></th>
<th>Number (thousands)</th>
<th>Rate (per 100 000 population)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total TB incidence</td>
<td>30 (21–41)</td>
<td>71 (49–98)</td>
</tr>
<tr>
<td>HIV-positive TB incidence</td>
<td>0.97 (0.3–2)</td>
<td>2.3 (0.72–4.8)</td>
</tr>
<tr>
<td>MDR/RRTB incidence</td>
<td>1.1 (0.61–1.7)</td>
<td>2.6 (1.5–4.1)</td>
</tr>
<tr>
<td>HIV-negative TB mortality</td>
<td>4.6 (2.9–6.8)</td>
<td>11 (6.9–16)</td>
</tr>
<tr>
<td>HIV-positive TB mortality</td>
<td>0.3 (0.093–0.63)</td>
<td>0.72 (0.22–1.5)</td>
</tr>
</tbody>
</table>

#### Estimated proportion of TB cases with MDR/RRTB, 2018

- **New cases**: 2.9% (1.7–4.1)
- **Previously treated cases**: 13% (8.6–17)

#### TB case notifications, 2018

- **Total new and relapse**: 20,117
  - % tested with rapid diagnostics at time of diagnosis: 18%
  - % with known HIV status: 34%
  - % pulmonary: 73%
  - % bacteriologically confirmed: 50%
  - % children aged 0-14 years: 10%
  - % women: 33%
  - % men: 57%

#### Universal health coverage and social protection

- **TB treatment coverage (notified/estimated incidence), 2018**: 67% (49–98)
- **TB patients facing catastrophic total costs**: 17% (9–27)

#### Drug-resistant TB care, 2018

- % of bacteriologically confirmed TB cases tested for rifampicin resistance: 118%
  - New cases: 20%
  - Previously treated cases: 118%

#### Treatment success rate and cohort size

<table>
<thead>
<tr>
<th></th>
<th>Success</th>
<th>Cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td>New and relapse cases registered in 2017</td>
<td>80%</td>
<td>20,188</td>
</tr>
<tr>
<td>Previously treated cases, excluding relapse, registered in 2017</td>
<td>73%</td>
<td>914</td>
</tr>
<tr>
<td>MDR/RRTB cases started on second-line treatment in 2016</td>
<td>84%</td>
<td>133</td>
</tr>
<tr>
<td>XDR-TB cases started on second-line treatment in 2016</td>
<td>0%</td>
<td>1</td>
</tr>
</tbody>
</table>

#### TB preventive treatment, 2018

- % of HIV-positive people (newly enrolled in care) on preventive treatment: 17% (15–18)
- % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment: 17% (15–18)

#### TB financing, 2019

- National TB budget (US$ millions): 12
  - Funding source: 1% domestic, 42% international, 56% unfunded

---

© Ranges represent uncertainty intervals

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

---

Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries. Generated: 2020-03-19

Data: www.who.int/tb/data